Invasive disease with non-typhoidal Salmonella in SSA is associated with increasing antibiotic resistance (AMR) and has been classified by the World Health Organization as high priority for developing new antibiotics. Despite high case fatality rates, particularly in children <5 years of age in SSA countries, no vaccine is currently available. The burden caused by NTS infections and increasing AMR strongly encourage for prompt development of an effective vaccine. A novel vaccine, is currently being developed by GSK Biologicals and GSK Vaccines Institute for Global Health, targeting the serovars Typhimurium and Enteritidis, the most common causative agents of African invasive NTS. Within a large consortium, a paediatric Phase I/II study will be launched early in 2021 in Ghana. The focus of our group will be on antibiotic resistant genotypes of iNTS-causing Salmonella strains. The information gained will not only inform on circulating Salmonella serovars and genotypes but will also inform on the development of AMR pathogens in SSA.

Partners:

Kwame Nkrumah University of Science and Technology (KNUST), Ghana

Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana

Agogo Presbyterian Hospital, Agogo, Ghana

University of Siena, Italy

MMGH Consulting GmbH, Switzerland

GSK Vaccine Institute for Global Health (GVGH), Italy

Funding:

European and Developing Countries Clinical Trials Partnership (EDCTP)